A Potentially Serious Adverse Effect of GLP-1 Receptor Agonists

Overview

Journal Acta Pharm Sin B

Publisher Elsevier

Specialty Pharmacology

Date 2023 May 30

PMID 37250165

Authors

Jinmiao Lu

Hao Liu

Qingtong Zhou

Ming-Wei Wang

Zhiping Li

Affiliations

Soon will be listed here.

Citing Articles

Acute Functional Gastric Outlet Obstruction Associated With Low-Dose Tirzepatide.

Iskander M, Wadhwa M, Kim Y, Singh N, Pathak P Cureus. 2025; 17(1):e78090.

PMID: 40026949 PMC: 11867769. DOI: 10.7759/cureus.78090.

Astragalus Mongholicus Polysaccharides Alleviate Kidney Injury in Rats with Type 2 Diabetes Through Modulation of Oxidation, Inflammation, and Gut Microbiota.

Xu G, Yuan H, Liu J, Wang X, Ma L, Wang Y Int J Mol Sci. 2025; 26(4).

PMID: 40003935 PMC: 11855448. DOI: 10.3390/ijms26041470.

Management of Overweight and Obesity in Patients With Inflammatory Bowel Disease.

Shneyderman M, Freid H, Kohler D, Peraza J, Haskey N, Abbott E Gastroenterol Hepatol (N Y). 2025; 20(12):712-722.

PMID: 39886003 PMC: 11776002.

Does Incretin Agonism Have Sustainable Efficacy?.

Janket S, Chatanaka M, Sohaei D, Tamimi F, Meurman J, Diamandis E Cells. 2024; 13(22).

PMID: 39594592 PMC: 11592889. DOI: 10.3390/cells13221842.

Tirzepatide-Associated Colonic Ischemia.

Bayless D, Singh J, Park B, Sweetser S ACG Case Rep J. 2024; 11(11):e01551.

PMID: 39507503 PMC: 11540430. DOI: 10.14309/crj.0000000000001551.

References

Butler P, Elashoff M, Elashoff R, Gale E . A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?. Diabetes Care. 2013; 36(7):2118-25. PMC: 3687282. DOI: 10.2337/dc12-2713. View

Prillaman M . The 'breakthrough' obesity drugs that have stunned researchers. Nature. 2023; 613(7942):16-18. DOI: 10.1038/d41586-022-04505-7. View

Jeppesen P . Gut hormones in the treatment of short-bowel syndrome and intestinal failure. Curr Opin Endocrinol Diabetes Obes. 2014; 22(1):14-20. DOI: 10.1097/MED.0000000000000120. View

Grill H . A Role for GLP-1 in Treating Hyperphagia and Obesity. Endocrinology. 2020; 161(8). PMC: 7899438. DOI: 10.1210/endocr/bqaa093. View

Reinshagen K, Kabs C, Wirth H, Hable N, Brade J, Zahn K . Long-term outcome in patients with short bowel syndrome after longitudinal intestinal lengthening and tailoring. J Pediatr Gastroenterol Nutr. 2008; 47(5):573-8. DOI: 10.1097/mpg.0b013e31816232e3. View

Gudin B, Ladhari C, Robin P, Laroche M, Babai S, Hillaire-Buys D . Incretin-based drugs and intestinal obstruction: A pharmacovigilance study. Therapie. 2020; 75(6):641-647. DOI: 10.1016/j.therap.2020.02.024. View

Reiner J, Thiery J, Held J, Berlin P, Skarbaliene J, Vollmar B . The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel. Ann N Y Acad Sci. 2022; 1514(1):132-141. DOI: 10.1111/nyas.14791. View

Skibicka K . The central GLP-1: implications for food and drug reward. Front Neurosci. 2013; 7:181. PMC: 3796262. DOI: 10.3389/fnins.2013.00181. View

Hvistendahl M, Brandt C, Tribler S, Naimi R, Hartmann B, Holst J . Effect of Liraglutide Treatment on Jejunostomy Output in Patients With Short Bowel Syndrome: An Open-Label Pilot Study. JPEN J Parenter Enteral Nutr. 2016; 42(1):112-121. DOI: 10.1177/0148607116672265. View

10.

Simonsen L, Pilgaard S, Orskov C, Rosenkilde M, Hartmann B, Holst J . Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats. Am J Physiol Gastrointest Liver Physiol. 2007; 293(1):G288-95. DOI: 10.1152/ajpgi.00453.2006. View

11.

Kunkel D, Basseri B, Low K, Lezcano S, Soffer E, Conklin J . Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome. Neurogastroenterol Motil. 2011; 23(8):739-e328. DOI: 10.1111/j.1365-2982.2011.01723.x. View

12.

Reiner J, Berlin P, Held J, Thiery J, Skarbaliene J, Griffin J . Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel. JPEN J Parenter Enteral Nutr. 2021; 46(5):1107-1118. DOI: 10.1002/jpen.2286. View

13.

Faillie J, Yin H, Yu O, Herrero A, Altwegg R, Renoux C . Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes. Clin Pharmacol Ther. 2021; 111(1):272-282. DOI: 10.1002/cpt.2430. View